Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
4.030
-0.070 (-1.71%)
At close: Aug 28, 2026, 4:00 PM EDT
4.035
+0.005 (0.12%)
After-hours: Aug 28, 2026, 4:10 PM EDT
Kalaris Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Kalaris Therapeutics stock has a consensus rating of "Buy" and an average price target of $18.71. The average 1-year stock price forecast is 364.27% higher than the current stock price, while the lowest is $7.00 (+73.70%) and the highest is $25 (+520.35%).
Price Target: $18.71 (+364.27%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kalaris Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $14 | Buy | Reiterates | $14 | +247.39% | Aug 12, 2026 |
| Wedbush | Wedbush | Buy Reiterates $17 | Buy | Reiterates | $17 | +321.84% | Aug 11, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 11, 2026 |
| TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jun 15, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $26 → $25 | Buy | Maintains | $26 → $25 | +520.35% | May 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.01
from -2.85
EPS Next Year
-1.99
from -2.01
EPS and Forward PE are based on non-GAAP adjusted numbers.